medmix AG
SIX:MEDX.SW
9.62 (CHF) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) CHF.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 120.6 | 120.6 | 238.5 | 119.25 | 248.1 | 124.05 | 226.5 | 113.25 | 250.6 | 125.3 | 229 | 114.5 | 228.3 | 114.15 | 185.2 | 92.6 | 166.1 | 83.05 |
| Cost of Revenue
| 80.3 | 80.3 | 162.8 | 81.4 | 166.1 | 83.05 | 149 | 76.45 | 152.7 | 75.7 | 139.6 | 69.8 | 136.5 | 68.25 | 121.5 | 60.75 | 108.7 | 54.35 |
| Gross Profit
| 40.3 | 40.3 | 75.7 | 37.85 | 82 | 41 | 77.5 | 36.8 | 97.9 | 49.6 | 89.4 | 44.7 | 91.8 | 45.9 | 63.7 | 31.85 | 57.4 | 28.7 |
| Gross Profit Ratio
| 0.334 | 0.334 | 0.317 | 0.317 | 0.331 | 0.331 | 0.342 | 0.325 | 0.391 | 0.396 | 0.39 | 0.39 | 0.402 | 0.402 | 0.344 | 0.344 | 0.346 | 0.346 |
| Reseach & Development Expenses
| 6.85 | 6.85 | 12.8 | 6.8 | 12.9 | 6.45 | 11.3 | 5.85 | 12.3 | 6.15 | 10.8 | 5.65 | 12.2 | 6.1 | 10.6 | 5.3 | 9.6 | 4.8 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 26.85 | 26.85 | 61.8 | 30.9 | 57.2 | 28.6 | 50.3 | 25.25 | 52.7 | 26.25 | 48.7 | 24.35 | 46.9 | 23.45 | 42.1 | 21.05 | 39.2 | 19.6 |
| Other Expenses
| 0.15 | 0 | 0 | 0 | 0 | 0 | -2.6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 33.85 | 34.2 | 74.6 | 38.5 | 70.1 | 34.55 | 64.2 | 36.15 | 65 | 41.25 | 59.5 | 30.65 | 59.1 | 30.25 | 52.7 | 26.85 | 48.8 | 24.75 |
| Operating Income
| 6.45 | 7 | 1.1 | 1.3 | 11.9 | 7.35 | 13.3 | 3.1 | 32.9 | 17.3 | 29.9 | 14.95 | 32.7 | 16.45 | 11 | 5.7 | 8.6 | 4.5 |
| Operating Income Ratio
| 0.053 | 0.058 | 0.005 | 0.011 | 0.048 | 0.059 | 0.059 | 0.027 | 0.131 | 0.138 | 0.131 | 0.131 | 0.143 | 0.144 | 0.059 | 0.062 | 0.052 | 0.054 |
| Total Other Income Expenses Net
| -3.15 | -3.7 | -7.2 | -4.35 | -2.9 | -2.85 | -29.1 | -3.85 | -4.9 | -10.45 | -5.8 | -2.9 | -5.5 | -2.85 | -4.9 | -2.7 | -4.2 | -2.3 |
| Income Before Tax
| 3.3 | 3.3 | -6.1 | -3.05 | 9 | 4.5 | -15.8 | -0.75 | 28 | 6.85 | 24.1 | 12.05 | 27.2 | 13.6 | 6.1 | 3 | 4.4 | 2.2 |
| Income Before Tax Ratio
| 0.027 | 0.027 | -0.026 | -0.026 | 0.036 | 0.036 | -0.07 | -0.007 | 0.112 | 0.055 | 0.105 | 0.105 | 0.119 | 0.119 | 0.033 | 0.032 | 0.026 | 0.026 |
| Income Tax Expense
| 0.5 | 0.5 | 0.5 | 0.25 | 1.7 | 0.85 | -3.6 | 1.95 | 4.2 | 2.25 | 2.8 | 1.4 | 4.5 | 2.25 | 0.5 | 0.2 | 0.4 | 0.2 |
| Net Income
| 2.6 | 2.6 | -7 | -3.5 | 7.3 | 3.65 | -12.2 | 1.2 | 23.8 | 4.6 | 21.3 | 10.65 | 22.7 | 11.35 | 5.6 | 2.8 | 4 | 2 |
| Net Income Ratio
| 0.022 | 0.022 | -0.029 | -0.029 | 0.029 | 0.029 | -0.054 | 0.011 | 0.095 | 0.037 | 0.093 | 0.093 | 0.099 | 0.099 | 0.03 | 0.03 | 0.024 | 0.024 |
| EPS
| 0.06 | 0.06 | -0.17 | -0.085 | 0.18 | 0.09 | -0.3 | 0.028 | 0.58 | 0.11 | 0.52 | 0.26 | 0.55 | 0.28 | 0.14 | 0.068 | 0.097 | 0.048 |
| EPS Diluted
| 0.06 | 0.06 | -0.17 | -0.085 | 0.18 | 0.09 | -0.3 | 0.029 | 0.58 | 0.11 | 0.52 | 0.26 | 0.55 | 0.28 | 0.14 | 0.068 | 0.097 | 0.048 |
| EBITDA
| 21.5 | 21.5 | 33.9 | 10.25 | 37.5 | 20.15 | 37.7 | 10.4 | 58.1 | 29.7 | 55.8 | 23.55 | 57.7 | 28.95 | 33.3 | 13.15 | 28.9 | 14.65 |
| EBITDA Ratio
| 0.178 | 0.178 | 0.142 | 0.086 | 0.151 | 0.162 | 0.166 | 0.092 | 0.232 | 0.237 | 0.244 | 0.206 | 0.253 | 0.254 | 0.18 | 0.142 | 0.174 | 0.176 |